**Provided by:**



**2021**

**The Intersection of Hypertension, Diabetes, and Lipids – Everything You Need to Know in Preventive Cardiology in 2021**

**October 1, 2021**

**7:45 AM - 2:00 PM**

**Live, Virtual**

**Target Audience**

This program has been designed for Internal Medicine - Clinical Cardiac Electrophysiology, Family Medicine, Internal Medicine - Advanced Heart Failure And Transplant Cardiology, Internal Medicine - Interventional Cardiology, Obstetrics And Gynecology, Public Health And General Preventive Medicine, Internal Medicine - Sports Medicine, Internal Medicine - Endocrinology, Diabetes And Metabolism, Internal Medicine, Internal Medicine - Geriatric Medicine, Internal Medicine - Nephrology, Preventive Medicine - Clinical Informatics, Internal Medicine - Cardiovascular Disease, Family Medicine - Geriatric Medicine, Obstetrics And Gynecology - Maternal And Fetal Medicine

**Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

1 Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations

2 Identify appropriate blood pressure goals and management in several special patient populations

3 Describe the controversies regarding the appropriate screening, confirmatory testing, and management of patients at risk for primary aldosteronism

4 Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia

5 Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention

**Session Educational Objectives**

After completing this educational activity, participants should be able to:

1 Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations

2 Identify appropriate blood pressure goals and management in several special patient populations

3 Describe the controversies regarding the appropriate screening, confirmatory testing, and management of patients at risk for primary aldosteronism

4 Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia

5 Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention

**Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Designation of Credit**

**Physicians**: Penn Medicine designates this live activity for a maximum of 4.75 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **4.75** contact hours.

**Pharmacists:**

This activity is approved for **4.75** contact hours

UAN Number: JA0000324-0000-21-042-L04-P

**PAs:**

Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **4.75** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Acknowledgement of Commercial Support\***

None



**Disclosure of Relevant Financial Relationships and Unapproved Uses of Products**

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of commercial interest/Nature of relationship** |
| Jordana Cohen, MD, MSCE | Co-Director, Faculty | Nothing to disclose - 10/26/2020 |
| Douglas S Jacoby, MD | Co-Director, Faculty | Advisor or Review Panel Member-AstraZeneca-Cholesterol Management|Advisor or Review Panel Member-Novartis-Cholesterol Management - 06/01/2021 |
| Debbie Cohen, MD | Course Director, Faculty | Nothing to disclose - 09/14/2021 |
| Archna Bajaj, MD, MSCE | Faculty | Grants/Research Support Recipient-Novartis AG|Grants/Research Support Recipient-Amgen|Grants/Research Support Recipient-REGENXBIO|Grants/Research Support Recipient-Pfizer, Inc. - 05/28/2021 |
| Maria Bonanni, MSN, CRNP | Faculty | Nothing to disclose - 08/16/2021 |
| Serena Cardillo, MD | Faculty | Nothing to disclose - 06/02/2021 |
| Jesse Goldman, MD | Faculty | Nothing to disclose - 09/27/2021 |
| Seyed Mehrdad Hamrahian, MD | Faculty | Nothing to disclose - 06/11/2021 |
| Michael R. Lattanzio, DO, FAAN | Faculty | Nothing to disclose - 08/27/2021 |
| Jennifer Lewey, MD, MPH | Faculty | Nothing to disclose - 06/21/2021 |
| Ilona Lorincz, MD, MSHP | Faculty | Nothing to disclose - 07/01/2021 |
| Arun Malhotra, MD | Faculty | Nothing to disclose - 09/27/2021 |
| Christopher McFadden, MD | Faculty | Nothing to disclose - 06/08/2021 |
| Daniel J Rader, MD | Faculty | Consultant-Alnylam-NA|Consultant-Novartis AG-NA|Consultant-Pfizer, Inc.-NA|Consultant-Verve-NA - 03/04/2021 |
| Mark Schutta, MD | Faculty | Spouse is Senior Scientist-Merck and Company, Inc.-Oncology, Diabetes, Metabolis - 04/14/2021 |
| Daniel Soffer, MD, FNLA | Faculty | writing support-Novartis AG-lipid management|Consultant-Ionis (formerly Akcea Therapeutics)-lipid management|industry-sponsored clinical trial participation-Ionis (formerly Akcea Therapeutics)-Lp(a) lowering|industry-sponsored clinical trial participation-Regeneron-lipid management|industry-sponsored clinical trial participation-RegenXBio-lipid management|industry-sponsored clinical trial participation-Astra-Zeneca-lipid management|industry-sponsored clinical trial participation-Amgen Inc-ASCVD risk mgmt - 06/03/2021 |
| Meshal Soni, MD | Faculty | Nothing to disclose - 07/28/2021 |
| Raymond Townsend, MD | Faculty | Consultant-Medtronic, Inc.-Hypertension - 08/04/2021 |
| Gayley B Webb, CRNP | Faculty, Nurse Planner | Nothing to disclose - 06/02/2021 |
| Diane Kim, PharmD | Faculty, Pharmacy Planner | Nothing to disclose - 05/01/2021 |
| Michael J Zumar, PA-C | Other Planning Committee Member |  |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected